Systematic reviews and meta-analysesFactors Associated With Progression of Barrett’s Esophagus: A Systematic Review and Meta-analysis
Section snippets
Methods
This systematic review was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions.21 It is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.22 A priori established protocol was followed.
Results
From a total of 2522 studies identified by our search strategy, 30 independent cohort studies that directly reported OR provided sufficient data to calculate OR between variables of interest and progression to HGD/EAC and were included in the analysis.9, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 Six studies were excluded because of overlapping populations.3, 18, 44, 45, 46, 47 Four studies were excluded because they reported outcomes in patients with baseline
Discussion
Several studies have tried to identify factors that predict malignant progression in BE subjects to risk stratify BE subjects but the results have not been consistent across studies. The current systematic review and meta-analysis identifies demographic factors, lifestyle factors, BE-related characteristics, and medications that had significant associations with the risk of progression to HGD/EAC in BE subjects without dysplasia or with LGD.
Acknowledgments
The authors thank Mr. Larry Prokop, Medical Librarian at the Mayo Clinic Library, for helping in the literature search for this systematic review and meta-analysis.
References (62)
The epidemic of oesophageal carcinoma: where are we now?
Cancer Epidemiol
(2016)- et al.
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis
Gastrointest Endosc
(2008) - et al.
The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus
Gastrointest Endosc
(2012) - et al.
The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends
Ann Oncol
(2012) - et al.
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States
Clin Gastroenterol Hepatol
(2009) - et al.
Persistence of nondysplastic Barrett’s esophagus is not protective against progression to adenocarcinoma
Clin Gastroenterol Hepatol
(2017) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus
Gastroenterology
(2011) - et al.
Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus
Gastroenterology
(2012) - et al.
Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus
Clin Gastroenterol Hepatol
(2013)
Medication usage and the risk of neoplasia in patients with Barrett's esophagus
Clin Gastroenterol Hepatol
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia
Clin Gastroenterol Hepatol
Barrett’s esophagus in women: demographic features and progression to high-grade dysplasia and cancer
Clin Gastroenterol Hepatol
Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus
Clin Gastroenterol Hepatol
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis
Clin Gastroenterol Hepatol
Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review
JAMA
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated
Am J Gastroenterol
ACG clinical guideline: diagnosis and management of Barrett’s esophagus
Am J Gastroenterol
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus
Gut
Barrett's esophagus
N Engl J Med
Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study
J Natl Cancer Inst
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis
Gut
Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study
Gut
Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression
Gut
Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus
Gut
Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study
Am J Gastroenterol
Impact of endoscopic surveillance on mortality from Barrett's esophagus–associated esophageal adenocarcinomas
Gastroenterology
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort
Gastroenterology
The annual risk of esophageal adenocarcinoma does not decrease over time in patients with Barrett’s esophagus
Am J Gastroenterol
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Ann Intern Med
Cited by (0)
Conflicts of interest The authors disclose no conflicts.